FOLH1 and neoplasm: At the later time of 4 h after injection, [61Cu]Cu-NODAGA-PSMA-I&T had improved tumor-to-background ratios, demonstrating the advantage of using a longer-t1/2 radionuclide to optimize radiotracer biodistribution and tumor-to-background contrast.